Literature DB >> 20096496

'A pill for every ill': explaining the expansion in medicine use.

Joan Busfield1.   

Abstract

This paper explores the major factors underpinning the expansion in medicine use over recent decades, using England as an example. It begins by constructing a 'progressive' model of the expansion and considers its limitations; it then uses a framework of countervailing powers to examine the contribution of key actors in the field. It examines the commercial orientation of the pharmaceutical industry and the strategies companies deploy to generate demand for their products. It explores the part played by doctors as researchers and gatekeepers to medicines, considering how features of medical knowledge and practice contribute to, rather than curtail, the expansion. It considers the role of the public as consumers of medicines, and the role of governments and insurance companies in both facilitating and controlling medicine use. Copyright 2009. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20096496     DOI: 10.1016/j.socscimed.2009.10.068

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  14 in total

1.  Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities.

Authors:  Jill A Fisher; Marci D Cottingham; Corey A Kalbaugh
Journal:  Soc Sci Med       Date:  2014-08-19       Impact factor: 4.634

2.  The evolution of Reference Drug Lists and Clinical Practice Guidelines in the public health system of a middle-income country.

Authors:  Israel Rico-Alba; Albert Figueras
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

3.  The strategic defense of physician autonomy: State public health agencies as countervailing powers.

Authors:  Laura Senier; Rachael Lee; Lauren Nicoll
Journal:  Soc Sci Med       Date:  2017-06-03       Impact factor: 4.634

Review 4.  Patients' expectations of medicines--a review and qualitative synthesis.

Authors:  Ulrica Dohnhammar; Joanne Reeve; Tom Walley
Journal:  Health Expect       Date:  2015-02-01       Impact factor: 3.377

Review 5.  Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?

Authors:  Courtney Davis
Journal:  Soc Sci Med       Date:  2014-12-02       Impact factor: 4.634

6.  The devil in the details: public health and depression.

Authors:  Andreas Vilhelmsson
Journal:  Front Public Health       Date:  2014-10-14

7.  Becoming a 'pharmaceutical person': Medication use trajectories from age 26 to 38 in a representative birth cohort from Dunedin, New Zealand.

Authors:  Peri J Ballantyne; Pauline Norris; Venkata Praveen Parachuru; W Murray Thomson
Journal:  SSM Popul Health       Date:  2017-11-12

8.  The shaping of pharmaceutical governance: the Israeli case.

Authors:  Philip Sax
Journal:  Isr J Health Policy Res       Date:  2014-05-27

9.  Potentially inappropriate prescribing in two populations with differing socio-economic profiles: a cross-sectional database study using the PROMPT criteria.

Authors:  Janine A Cooper; Frank Moriarty; Cristín Ryan; Susan M Smith; Kathleen Bennett; Tom Fahey; Emma Wallace; Caitriona Cahir; David Williams; Mary Teeling; Carmel M Hughes
Journal:  Eur J Clin Pharmacol       Date:  2016-01-28       Impact factor: 2.953

10.  Comprehension and compliance with the discharge advice and quality of life at home among the postoperative neurosurgery patients discharged from PGIMER, Chandigarh, India.

Authors:  Vishal Kumar; Amarjeet Singh; Manoj K Tewari; Sukhpal Kaur
Journal:  Asian J Neurosurg       Date:  2016 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.